# Disclosures

## Personal Commercial (36)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen Inc.</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Apex Innovation</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Arterez</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td></td>
<td>Predictive Diagnostic Tool for Family of Cardiac Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astra Zeneca</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td>Baim Institute</td>
<td>Consultant Fees/Honoraria</td>
<td>None ($0)</td>
<td>Acute Coronary Syndromes</td>
</tr>
<tr>
<td>Beckman Coulter</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td>BMS</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td></td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Cardionomics</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Cardiosounds</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td></td>
<td>Validation of CardioSound Non-Invasive Continuous Blood Pressure Recording</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies Other</td>
</tr>
<tr>
<td>EMCREG-International</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>General Cardiology Other</td>
</tr>
<tr>
<td>Emergencies in Medicine</td>
<td>Ownership Interest/Partnership/Principal</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Haymarket Media</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Medscape</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>General Cardiology</td>
</tr>
<tr>
<td>Mespere</td>
<td>Ownership Interest/Partnership/Principal</td>
<td>None ($0)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>My Patient Insight</td>
<td>Ownership Interest/Partnership/Principal</td>
<td>None ($0)</td>
<td>General Cardiology Other</td>
</tr>
<tr>
<td></td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Nabriva</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals</td>
<td>Research/Research Grants</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Ortho Diagnostics</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (≥ $5,000)</td>
<td>Acute Coronary Syndromes</td>
</tr>
</tbody>
</table>
### Cardiomyopathies

**PeerView**  
Consultant Fees/Honoraria: Significant (>= $5,000)  
**Other**

**PeerView**  
Consultant Fees/Honoraria: Significant (>= $5,000)  
**Other**

**Pfizer Inc**  
Research/Research Grants: Significant (>= $5,000)  
**Prevention**

**Portola**  
Consultant Fees/Honoraria: Modest (< $5,000)  
**Other**

**Precision PharmX**  
Ownership Interest/Partnership/Principal: None ($0)  
**General Cardiology Other**

**Roche Diagnostics**  
Research/Research Grants: Significant (>= $5,000)  
Heart Failure and Cardiomyopathies

**Roche Diagnostics**  
Consultant Fees/Honoraria: Significant (>= $5,000)  
Acute Coronary Syndromes

**Rosh Review**  
Consultant Fees/Honoraria: Modest (< $5,000)  
**General Cardiology**

**Sciex**  
Consultant Fees/Honoraria: Modest (< $5,000)  
**Other**

**Shire**  
Consultant Fees/Honoraria: Significant (>= $5,000)  
**Other**

**Shire**  
Research/Research Grants: Significant (>= $5,000)  
**Other**

**Siemens**  
Consultant Fees/Honoraria: Significant (>= $5,000)  
Acute Coronary Syndromes

**Vindico**  
Consultant Fees/Honoraria: Modest (< $5,000)  
**Other**

### Personal Non-Commercial (11)

<table>
<thead>
<tr>
<th>Non-Commercial Entity Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Self</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHRQ</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>American College of Emergency Physicians</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies Other</td>
</tr>
<tr>
<td>Blue Cross Blue Shield of MI Foundation</td>
<td>Research/Research Grants</td>
<td>Modest (&lt; $5,000)</td>
<td>Acute Coronary Syndromes</td>
</tr>
<tr>
<td>Emergency Medicine Foundation</td>
<td>Officer, Director, Trustee, or other Fiduciary Role</td>
<td>None ($0)</td>
<td>Other</td>
</tr>
<tr>
<td>Emergency Medicine Foundation</td>
<td>Research/Research Grants</td>
<td>None ($0)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Hospital Quality Foundation</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Michigan Department of Health and Human Services</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>Michigan Department of Health and Human Services</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (&gt;= $5,000)</td>
<td>Prevention</td>
</tr>
<tr>
<td>NIH/NHLBI</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>NIH/NIMHD</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>PCORI</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
</tbody>
</table>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (2)

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>Institutional Compensation Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Cardiology</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
<tr>
<td>Wayne State University</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
</tbody>
</table>
Expert Witness Testimony (1)

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Title</th>
<th>Represented</th>
<th>Description</th>
<th>Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>Pulmonary embolism</td>
<td>Plaintiff</td>
<td>Young male diagnosed with intermediate to high risk PE with fatal outcome.</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
</tbody>
</table>

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/8/2019
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/8/2019
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 11/8/2019
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 11/8/2019

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.